Masterhead

Thank you for visiting foster-city.gate2bay.com. Fill in the form below:

Name/Corp.:

E-mail:

Subject:

Message:

Gilead Presents New Phase 2 Data on Bictegravir, an Investigational Integrase Strand Transfer Inhibitor for the Treatment of HIV

Published Monday February 27

SEATTLE–(BUSINESS Mon Feb 13 Gilead Sciences, Incorporated (NASDAQ: GILD) today announced data from a Phase two study evaluating the efficacy, safety and tolerability of a combination of bictegravir (75 mg) (BIC) and emtricitabine/tenofovir alafenamide (200/25 mg) (FTC/TAF) versus dolutegravir (50 mg) (DTG) and emtricitabine/tenofovir alafenamide (200/25 mg) (FTC/TAF) in treatment naïve, HIV-1 infected adults.

Bictegravir, including in combination with FTC/TAF as a single tablet regimen, is an investigational treatment that has not been determined to be safe or efficacious.

Article length: About 760 words.
Tags: Foster City
Read more at Drugs

google-468x60a

Share This Post

DeliciousDiggGoogleStumbleuponRedditTechnoratiYahooBloggerMyspaceRSS

selfad-writeart-b